Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors

@inproceedings{Fujiwara2015EfficacyAS,
  title={Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors},
  author={Masateru Fujiwara and Fumiaki Isohashi and Seiji Mabuchi and Yasuo Yoshioka and Yuji Seo and Osamu Suzuki and Iori Sumida and Kazuhiko Hayashi and Tadashi Kimura and Kazuhiko Ogawa},
  booktitle={Journal of radiation research},
  year={2015}
}
Cisplatin-based concurrent chemoradiotherapy (CCRT) is a standard treatment for cervical cancer, but nedaplatin-based CCRT is not routinely administered. We evaluated the efficacy and safety of nedaplatin-based CCRT (35 mg/m(2) weekly) and analyzed prognostic factors for survival among 52 patients with International Federation of Gynecology and Obstetrics… CONTINUE READING